Mallinckrodt plc (MNK) : The consensus on Mallinckrodt plc (MNK) based on 13 analyst recommendation on the company stock is 1.04, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 12 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future.
Mallinckrodt plc (MNK) : The highest level Mallinckrodt plc (MNK) is projected to reach is $115 for the short term and the lowest estimate is at $82. The consolidated price target from 12 rating analysts who initiate coverage on the stock is $94.33 and the possibility the share price can swing is $9.23.
Shares of Mallinckrodt Public Limited Company rose by 4.65% in the last five trading days and 24.32% for the last 4 weeks. Mallinckrodt Public Limited Company is up 36.45% in the last 3-month period. Year-to-Date the stock performance stands at 11.3%. Mallinckrodt plc (NYSE:MNK): stock turned positive on Tuesday. Though the stock opened at $82.28, the bulls momentum made the stock top out at $83.45 level for the day. The stock recorded a low of $82.01 and closed the trading day at $83.06, in the green by 1.94%. The total traded volume for the day was 1,443,848. The stock had closed at $81.48 in the previous days trading.
Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product.